Intas’ Response To Second Data Integrity Inspection Still Did Not Go Far Enough, US FDA Says

Intas – the the troubled Indian firm at the center of the cisplatin shortage – may have punished workers for their visual-inspection subterfuge, but it also should have gone after managers, the FDA asserted in a second data integrity warning letter in four months.

Ampoule inspection machine
machines counted particles; humans adjusted the counts • Source: Shutterstock

How would Intas Pharmaceuticals Ltd. respond to a second US FDA inspection to uncover serious data integrity failures just months after the first?

During the first, panicky workers at an Intas plant near Matoda, India, tore doctored weight balance sheets, poured pungent acetic...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance